- Home
- DMAC vs MG Comparison
DMAC vs MG Comparison
Compare DMAC & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MG
- Stock Information
- Founded
- DMAC 2000
- MG 1978
- Country
- DMAC United States
- MG United States
- Employees
- DMAC N/A
- MG N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MG Military/Government/Technical
- Sector
- DMAC Health Care
- MG Consumer Discretionary
- Exchange
- DMAC Nasdaq
- MG Nasdaq
- Market Cap
- DMAC 310.1M
- MG 303.1M
- IPO Year
- DMAC N/A
- MG 2009
- Fundamental
- Price
- DMAC $5.98
- MG $9.65
- Analyst Decision
- DMAC Strong Buy
- MG
- Analyst Count
- DMAC 3
- MG 0
- Target Price
- DMAC $12.33
- MG N/A
- AVG Volume (30 Days)
- DMAC 314.0K
- MG 121.9K
- Earning Date
- DMAC 08-12-2025
- MG 08-06-2025
- Dividend Yield
- DMAC N/A
- MG N/A
- EPS Growth
- DMAC N/A
- MG N/A
- EPS
- DMAC N/A
- MG 0.37
- Revenue
- DMAC N/A
- MG $702,445,000.00
- Revenue This Year
- DMAC N/A
- MG $0.81
- Revenue Next Year
- DMAC N/A
- MG $15.30
- P/E Ratio
- DMAC N/A
- MG $26.45
- Revenue Growth
- DMAC N/A
- MG N/A
- 52 Week Low
- DMAC $3.19
- MG $7.06
- 52 Week High
- DMAC $6.82
- MG $12.44
- Technical
- Relative Strength Index (RSI)
- DMAC 65.09
- MG 72.83
- Support Level
- DMAC $5.90
- MG $8.96
- Resistance Level
- DMAC $6.18
- MG $9.99
- Average True Range (ATR)
- DMAC 0.39
- MG 0.28
- MACD
- DMAC 0.02
- MG 0.06
- Stochastic Oscillator
- DMAC 79.10
- MG 75.36
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.